PTC Therapeutics PTCT Noncash Royalty Revenue Sale Of Future Royalties

Noncash Royalty Revenue Sale Of Future Royalties at other companies

ESP

ESPRESPR

$18.48M+76.3%

XencorXNCR

$12.79M-31.3%

XencorXNCR

$12.79M-31.3%

Arbutus Biopharma CorporationABUS

$181K-59.6%

Nektar TherapeuticsNKTR

$10.9M+3.8%

AnaptysBio, Inc.ANAB

$20.86M+15.5%

FAQ

What is PTC Therapeutics's noncash royalty revenue sale of future royalties?

PTC Therapeutics (PTCT) reported noncash royalty revenue sale of future royalties of $46.84M in Q1 2026.

How has PTC Therapeutics's noncash royalty revenue sale of future royalties changed year-over-year?

PTC Therapeutics's noncash royalty revenue sale of future royalties increased by 42.0% year-over-year, from $32.97M to $46.84M.

What is the long-term trend for PTC Therapeutics's noncash royalty revenue sale of future royalties?

Over 4 years (2021 to 2025), PTC Therapeutics's noncash royalty revenue sale of future royalties has grown at a 76.7% compound annual growth rate (CAGR), from $23.46M to $228.57M.

What does noncash royalty revenue sale of future royalties mean?

Represents the non-cash portion of revenue recognized from the monetization of future royalty streams. This adjustment reconciles the difference between cash receipts from royalty financing arrangements and the revenue recognized under accounting standards.